Orchestra BioMed Holdings, Inc. (OBIO)

Orchestra BioMed's stock (OBIO) has experienced a price decline of 4.91% from March 31, 2025, to March 30, 2026. In March 2026, the company reported its full-year 2025 financial results and surpassed Q4 earnings and revenue estimates. The company reported a strong cash position as of December 31, 2025, with additional funds expected from Medtronic, Ligand, and Haemonetics. Analyst firms have maintained "Buy" or "Overweight" recommendations for OBIO. An investor who bought $1,000 worth of Orchestra BioMed Holdings stock at the IPO in 2020 would have seen a significant decline in value by April 2026.

There is no indication of significant demand seasonality for Orchestra BioMed Holdings, Inc.'s products and services, as they address chronic conditions with relatively stable demand throughout the year.

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's business model centers on developing innovative solutions and technologies, then collaborating with leading medical device companies for global commercialization. Its flagship product candidates include Atrioventricular Interval Modulation Therapy (AVIM Therapy), a bioelectronic therapy designed to lower blood pressure for hypertension treatment, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), a drug/device combination product candidate for atherosclerotic artery disease treatment.

Orchestra BioMed Holdings, Inc. is headquartered in New Hope, Pennsylvania, United States. The company's business model emphasizes driving successful global commercialization of its products through partnerships.

Orchestra BioMed's reputation has been positively impacted by the FDA Breakthrough Device Designation for its AVIM Therapy, surpassing Q4 earnings and revenue estimates, and securing capital and strategic partnerships with major medical device companies. Analyst recommendations maintaining "Buy" or "Overweight" ratings further support a positive brand image.

Orchestra BioMed Holdings, Inc. has 68 institutional owners and shareholders holding a total of 21,887,988 shares. Institutional shareholders own 37.08% of the company, while Orchestra BioMed insiders own 61.27%, and retail investors own 1.64%. RTW Investments LP is the largest individual shareholder, owning 13.93 million shares, representing 23.80% of the company.